AKT1 and lung carcinoma: IGF2 produced by CAFs binds to the IGF1 receptor in lung cancer cells and activates the AKT/Sox2 pathway, leading to increased expression of P-glycoprotein, which can pump out chemotherapeutic agents reaching the tumor.